Skip to main content
. 2021 Sep 2;147(10):1–8. doi: 10.1001/jamaoto.2021.2191

Figure 3. Safety of Neoadjuvant Immunotherapy for Resectable Head and Neck Cancer.

Figure 3.

Preoperative grade 3 to 4 treatment-related adverse events (TRAEs) (A) and surgical delay rates (B) in clinical trials. PD-1/PD-L1 indicates programmed cell death 1/programmed cell death 1 ligand 1.